Skip to main content

ABI Sues Stratagene in Europe for Allegedly Infringing qPCR Patent

NEW YORK (GenomeWeb News) — Applied Biosystems' parent company has sued Stratagene in the Netherlands and France for allegedly infringing an ABI patent, Stratagene said in a filing with the US Securities and Exchange Commission yesterday.
 
According to the filing, on May 23 Stratagene received a writ of summons filed by Applera in the District of The Hague in the Netherlands alleging that Stratagene's Mx3000P, Mx3005P, Mx4000P, and "certain related reagents" infringe ABI’s EU patent No. 0 872 562 B1.
 
Stratagene said it must appear at a preliminary court hearing on July 4 in the Netherlands, and that the company appoint an attorney from the Paris Bar by Aug. 9.
 
Applera wants the courts to bar Stratagene from selling these products in the Netherlands, France, and "certain other European nations."
 
Stratagene said that Applera's claims are "without merit" and that it intends to "vigorously defend these actions.”

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.